Adnan Kastrati has found that a study comparing the two main drug eluting stents in terms of late lumen loss suggests sirolimus has the upper hand over paclitaxel among diabetic patients. Marie-Claude Morice’s study has also found sirolimus stents to be slightly superior in terms of neointimal growth rates among non-diabetic patients.

Nikolaus Marx‘s investigation shows that the oral anti-diabetic drug, pioglitazone, can be used to reduce the formation of new tissue inside a stent in non-diabetics, and could reduce restenosis rates.

John Cleland and Kenneth Ellenbogen review findings that cardiac resynchronisation – or atrial-biventricular pacing – extends life in patients with severe heart failure and cardiac dysynchrony.

Germano Di Sciascio and Lloyd Klein discuss how doubling the usual clopidogrel dose may be best in coronary intervention.

Zhenming Chen & Rory Collins found that adding clopidogrel to the usual care of patients with acute myocardial infarction is of clear benefit according to the findings of the 46,000 patient COMMIT Study. However, the use of metoprolol in the same acute MI patients is not endorsed for all patients.